UPLIFT study - understanding potential long-term impacts on function with tiotropium - and sub-analyses. Bibliographic resume of the obtained results

References

• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Guía española de la COPD (GesCOPD). Actualización 2014. Arch Bronconeumol. 2014;50(Supl 1):1–16.
   PubMedGoogle Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–555.
   PubMed Web of Science ®Google Scholar
• Montes de Oca M, López Varela MV, Acuña A, et al. Guía de práctica clínica de la enfermedad pulmonar obstructiva crónica (COPD) ALAT-2014: Preguntas y respuestas. Arch Bronconeumol. 2015;51:403–416.
   PubMed Web of Science ®Google Scholar
• Alcázar Navarrete B, Casanova C, Miravitlles M, et al. Documento de consenso. Uso adecuado de los corticoides inhalados en la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2015;51:193–198.
   PubMedGoogle Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez García MA. Impacto de los estudios de eficacia y mortalidad (TORCH y UPLIFT) en el tratamiento broncodilatador de la EPOC. Arch Bronconeumol. 2009;45(Supl 5):14–20.
   PubMedGoogle Scholar
• Decramer M, Celli B, Kesten S, et al.; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–1178.
   PubMed Web of Science ®Google Scholar
• Anzueto A, Niewoehner DE, Leimer I, et al. A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium. Respir Med. 2013;107:1912–1922.
   PubMed Web of Science ®Google Scholar
• Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996;154(4 Pt 1):959–967.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–555.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli BR, Decramer M, et al. Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. COPD. 2012;9(3):289–296.
   PubMedGoogle Scholar
• Morice AH, Celli B, Kesten S, et al. COPD in young patients: A pre-spe. cified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med. 2010;104(11):1659–1667.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Kesten S, et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J. 2010;35(2):287–294.
   PubMed Web of Science ®Google Scholar
• Tashkin D, Celli B, Kesten S, et al. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med. 2010;104(10):1495–1504.
   PubMed Web of Science ®Google Scholar
• Troosters T, Celli B, Lystig T, et al.; Investigators Uplift. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J. 2010;36(1):65–73.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Sharafkhaneh A, Celli B, et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011;12:6.
   PubMed Web of Science ®Google Scholar
• Halpin DM, Decramer M, Celli B, et al. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial. Lung. 2011;189(4):261–268.
   PubMed Web of Science ®Google Scholar
• Decramer M, Molenberghs G, Liu D, et al.; UPLIFT investigators. Premature discontinuation during the UPLIFT study. Respir Med. 2011;105(10):1523–1530.
   PubMed Web of Science ®Google Scholar
• Celli BR, Decramer M, Lystig T, et al. Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respir Res. 2012;13:66.
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Kesten S, et al.; UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948–955.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Li N, Halpin D, et al. Annual rates of change in pre- vs. post- bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respir Med. 2013;107(12):1904–1911.
   PubMed Web of Science ®Google Scholar
• Janssens W, Liub Y, Liu D, et al. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT®). Respir Med. 2013;107:1409–1416.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Li N, Kleerup EC, et al. Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. Respir Res. 2014;15:102.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013 Feb 15;187(4):347–365. doi:10.1164/rccm.201204-0596PP
   Google Scholar
• Goossens LM, Leimer I, Metzdorf N, et al. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med. 2014;14:163.
   PubMed Web of Science ®Google Scholar
• Burgel PR, Paillasseur JL, Dusser D, et al. Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respir Res. 2014;15:64.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Leimer I, Metzdorf N, et al. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial. Respir Res. 2015;16:65.
   PubMed Web of Science ®Google Scholar
• Ancochea Bermúdez J, Girón Moreno RM, Ruiz Cobos MA. Tiotropio: análisis crítico. Arch Bronconeumol. 2005;41(Supl3):39–47.
   Google Scholar